Transphorm Inc Intrinsic Value Calculator – TRANSPHORM INC Reports First Quarter FY2024 Earnings Results
August 27, 2023
🌥️Earnings Overview
Transphorm Inc ($NASDAQ:TGAN). released its financial data for the first quarter of fiscal year 2024 which ended on June 30, 2023. Total revenue for the period was USD 5.9 million, representing an increase of 14.0% compared to the same quarter in the prior year. Net income for the quarter was USD -7.4 million, compared to a net loss of USD -5.4 million in the same quarter of the previous year.
Share Price
On Monday, TRANSPHORM INC reported its first-quarter earnings results for FY2024. After the financial results were announced, the company’s stock opened at $2.8 and closed at $2.9, up by 3.2% from last closing price of 2.8. This indicates that the investors are pleased with the performance of the company in the first quarter. The company also reported a significant increase in its cash and cash equivalents, which is an encouraging sign.
Overall, this was a strong quarter for TRANSPHORM INC, and investors have responded positively to the earnings report. The company has clearly demonstrated its ability to grow and expand, making it a great investment opportunity for those looking for long-term returns. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Transphorm Inc. More…
| Total Revenues | Net Income | Net Margin |
| 17.24 | -38.3 | -189.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Transphorm Inc. More…
| Operations | Investing | Financing |
| -30.37 | -9.5 | 0.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Transphorm Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 33.72 | 10.89 | 0.38 |
Key Ratios Snapshot
Some of the financial key ratios for Transphorm Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.5% | – | -186.4% |
| FCF Margin | ROE | ROA |
| -212.2% | -94.7% | -59.6% |
Analysis – Transphorm Inc Intrinsic Value Calculator
As GoodWhale, we have conducted an analysis of TRANSPHORM INC‘s wellbeing. Based on our proprietary Valuation Line, we have determined that the fair value of a TRANSPHORM INC share is around $3.7. As of now, the stock is being traded at $2.9, indicating that it is undervalued by about 20.9%. This provides an attractive opportunity for investors to purchase the stock at an attractive price point. More…
Peers
Its competitors are Transcom Inc, Spectra7 Microsystems Inc, and Asmedia Technology Inc.
– Transcom Inc ($TWSE:5222)
Transcom Inc is a publicly traded company with a market capitalization of 8.65 billion as of 2022. The company has a return on equity of 8.56%. Transcom Inc is engaged in the business of providing telecommunications and information services to consumers, businesses, and government organizations.
– Spectra7 Microsystems Inc ($TSXV:SEV)
Spectra7 Microsystems Inc is a Canadian company that designs and manufactures high-speed semiconductor chips. The company has a market cap of 18.51M as of 2022 and a Return on Equity of -345.75%. The company’s products are used in a variety of applications including virtual reality, augmented reality, mixed reality, and data center connectivity.
– Asmedia Technology Inc ($TWSE:5269)
Asmedia Technology Inc is a fabless semiconductor company that designs and markets high-speed integrated circuits. The company’s products are used in a variety of applications, including USB 3.0 controllers, SATA and PCI Express controllers, and integrated circuits for Ethernet and WiFi connectivity. Asmedia Technology Inc has a market cap of 41.69B as of 2022, a Return on Equity of 14.74%. The company’s products are used in a variety of applications, including USB 3.0 controllers, SATA and PCI Express controllers, and integrated circuits for Ethernet and WiFi connectivity.
Summary
TRANSPHORM INC has reported its earnings results for the first quarter of FY2024, ending June 30 2023. Total revenue for the quarter was USD 5.9 million, an impressive 14.0% year over year increase. Net income for the quarter was USD -7.4 million, slightly worse than -5.4 million from the same period last year.
Nonetheless, the stock price moved up the same day, indicating that investors are still optimistic about the company’s future prospects. As such, investors may consider investing in TRANSPHORM INC, particularly if they believe the company will be able to continue to grow its revenues and turn a profit in the coming quarters.
Related Posts
Recent Posts
